The World Health Organization estimates that 35.3 million people were living with the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/ AIDS) in 2012, with 2.3 million new annual infections globally. 1 Yet, AIDS-related deaths declined from 2.3 million in 2005 to 1.6 million in 2012, 1 thanks to the introduction and increased use of highly active antiretroviral therapy (HAART) and to growing education and prevention programs. 1 Because HIV-infected individuals are living longer, clinicians are observing new pathologies in this patient population. HIV-positive patients remain at increased risk for developing cardiovascular pathologies, including cardiovascular disease, myocardial infarction, and stroke. 2, 3 The relative risk of coronary heart disease is significantly higher in HIV patients than in controls, ranging from 1.53 in women aged 25 to 34 to 6.76 in men aged 18 to 24. 4 The rate of acute myocardial infarction was 11.13 per 1000 person-years in HIV-infected patients compared with 6.98 for patients without HIV, and the relative risk of myocardial infarction was 1.75 in HIV-infected patients. 5 One study found HIV-infected patients had an increased incidence of ischemic stroke (5.27 vs 3.75 per 1000 person-years) and that HIV was an independent predictor of stroke when controlled for stroke risk factors. 6 Moreover, HIV patients have higher rates of other conditions that can damage the vascular system. For instance, HIV-positive individuals have higher rates of dyslipidemia (23.3% vs 17.6%) compared with the general population. 5 HIV patients also show signs of chronic inflammation, as demonstrated by elevated levels of inflammation markers, such as high-sensitivity C-reactive protein (hs-CRP) and interleukin (IL)-6, cytokines, and markers of endothelial dysfunction such as soluble intercellular adhesion molecule 1 (sICAM-1). 7, 8 Although in some instances HIV patients have higher rates of traditional cardiovascular risk factors, such as smoking, diabetes mellitus, and hypertension, 9 this cannot explain all of the cardiovascular pathologies observed in HIV patients. Recent evidence suggests that many vascular complications seen in HIV patients proceed through different mechanisms than for HIV-negative patients. For instance, in a comparative ultrasound study, Maggi et al 10 found structural differences in lesions on the proximal area of the aorta of HIV patients compared with plaques in atherosclerosis patients. HIV-positive patients were more likely (81.8% vs 29%) to have isohypoechogenic lesions that were homogenous in the parietal and endoluminal portions, and these lesions more often had smooth or slightly irregular surfaces compared with HIVnegative atherosclerotic patients. 10 Overall, the lesions found in HIV-positive patients more closely resembled those of HIV-negative patients with arteritis than those of HIV-negative patients with atherosclerosis, leading to the hypothesis that carotid plaques may develop as a result of inflammation rather than atherosclerosis.
This pathology has several possible causes. HAART, especially the protease inhibitors (PIs), has been reported to cause changes in body fat distribution, lipid and glucose metabolism, and mitochondrial function. 11 The antiretrovirals have also been demonstrated to induce endothelial cell (EC) dysfunction, smooth muscle cell (SMC) proliferation, and neointimal hyperplasia. 12 In addition, HIV itself may contribute to atherosclerosis and other vascular complications. 13 HIV-induced immune dysfunction and dyslipidemia can lead to atherosclerotic plaque development and contribute to adverse cardiovascular events such as stroke or myocardial infarction. Moreover, HIV targets macrophages, ECs, platelets, and SMCs, contributing to atherosclerosis.
More research is needed into therapies to target this HIV-specific vasculopathy. The purposes of this review are to outline the mechanisms by which HIV and HIV medications can cause vascular complications and to identify strategic areas of research to treat these dysfunctions.
REVIEW I. HIV-specific contributions to vasculopathy/ pathogenesis
A. Metabolic/systemic effects of HIV. HIV infection can be responsible for multiple endocrine and metabolic disorders, particularly in treated patients who are living longer than before and are less susceptible to opportunistic infections and other complications of HIV. These systemic effects include dyslipidemia, lipodystrophy, and insulin resistance.
14 HIV patients also generally experience chronic inflammation, which can contribute to dyslipidemia and atherosclerosis.
1. Dyslipidemia. Dyslipidemia is more common in HIV-infected patients than in the general population. 15 This can be attributed to the use of PIs, discussed later, and to the virus itself. HIV-specific dyslipidemia is characterized by low high-density lipoprotein (HDL) cholesterol levels, high total cholesterol levels, and high triglyceride levels. 14 In a multicenter cohort study that measured serum lipid levels in seroconverters before and after starting HAART treatment, Riddler et al 16 confirmed that HIV was associated with low cholesterol levels, including lowered low-density lipoprotein (LDL) and HDL, an observation noted in earlier studies. 17 The cause of low cholesterol levels is multifactorial but is attributed to the virus itself, because serum total cholesterol and LDL increases after initiation of HAART. Low LDL is generally considered favorable from a cardiovascular standpoint; indeed, the low LDL and low HDL levels seen in HIV-infected individuals do not represent a typical atherogenic lipid profile. However, despite observed low LDL, low HDL in HIVinfected individuals is still correlated with cardiovascular disease and adverse cardiovascular events. 18 The immune system is activated in the early phases of HIV infection, resulting in a "cytokine storm." 14 Tumor necrosis factor alpha (TNF-a), IL-1, interferon-a, interferon-g, and other cytokines contribute to decreased HDL levels. 19 A recent review of atherosclerosis in HIV patients noted that infection impedes reverse cholesterol transport and limits anti-inflammatory properties, which alters HDL function. 13 In a 1-year, prospective study of HIV-positive patients, Rose et al 20 noted high rates of hypoalphalipoproteinemia, or HDL deficiency. Elevated triglyceride levels are also associated with advanced HIV, with a trend of hyperlipidemia. 21 Taken together, multiple studies indicate that HIV affects reverse cholesterol transport, resulting in low cholesterol levels and high triglyceride levels. It is postulated that HIV-infected individuals exhibit higher activity of lecithin-cholesterol acyltransferase, which enhances HDL maturation (Fig 1) . 20 However, although this finding would lead to increased reverse cholesterol transport activity, this is not observed in HIV patients, This may be due to an additional finding of increased levels of cholesteryl ester transfer protein in HIV-infected individuals, which increases transfer of cholesteryl esters from HDL to apolipoprotein (apo)-B-containing lipoproteins, which is proatherogenic. Thus, reverse cholesterol transport is inhibited in HIV-positive patients, leading to increased rates of hypoalphalipoproteinemia.
The effects of HIV on reverse cholesterol transport have downstream ramifications for the management of HIV-induced vasculopathy. Decreased HDL levels and elevated triglyceride levels lead to dyslipidemia, which is intimately related to stroke, coronary artery disease, and peripheral artery disease. Because HAART can reverse these metabolic effects of HIV, HAART may assist clinicians not only in controlling HIV levels but also in treating some of the cardiovascular consequences of the disease. It should be noted, however, that certain HAART regimens can cause dyslipidemia through other mechanisms (discussed below).
2. Chronic inflammation and immune activation. HIV-infected individuals are susceptible to chronic immune activation and inflammation, which can have several effects on the vascular system. HIV activates multiple inflammatory pathways, resulting in the release of cytokines and endothelial adhesion molecules expression. 3 In addition, HIV induces activation of monocytes/ macrophages, which are involved in the development of atherosclerosis. 3, 15 The specific effects of inflammation and immune activation on ECs and macrophages are discussed below.
Microbial translocation and low-grade endotoxemia are responsible for some of the chronic inflammation observed in HIV patients. 15 HIV is thought to cause depletion of CD4 T cells in the mucosal tissues. 22 Increased turnover of CD4 T cells occurs in the gut, and this can lead to microbial translocation, although this mechanism needs to be explored further. Moreover, the tight epithelial lining is compromised in HIV infection, and there is a loss of structural integrity, allowing microbes to translocate through the mucosal layer. 22 Microbial translocation leads to low-grade endotoxemia, which can cause chronic lowlevel inflammation and immune cell activation, primarily affecting T cells and monocytes. 23 Chronic, low-level, systemic inflammation can also lead to elevated levels of various inflammatory molecules that damage the endothelium, including IL-6, IL-18, CRP, and lipopolysaccharide. 15 IL-6, a proinflammatory cytokine, decreases lipoprotein lipase activity and increases macrophage uptake of lipids. In addition, IL-6, together with IL-1 and TNF-a, induce production of CRP, an acute-phase protein. CRP is elevated in patients with HIV and is associated with endothelial dysfunction. Moreover, CRP levels are negatively correlated with CD4 counts. IL-18, a marker of early-stage activation, is produced by macrophages and is elevated in patients with hypertension. 15 HIV-induced inflammation and atherosclerosis have been further linked by research on the C-C chemokine receptor (CCR) type 5 (CCR5) and its ligands, CCL3, CCL4, and CCL5 (regulated on activation normal T cellexpressed and secreted [RANTES] ). CCR5 is a coreceptor for HIV infection in macrophages. 24 The CCR5 deletion polymorphism CCR5-delta32 has been shown to confer resistance to HIV-1 infection.
25 CCL5 acting at CCR5 is involved in the recruitment of monocytes to atherosclerotic plaque, and the CCR5-delta32 deletion is also associated with reduced risk of cardiovascular disease in some studies. 25 Thus, drugs targeting CCR5, or CCR5 antagonists, may play a role in attenuating the effects of HIV as well as the development of atherosclerosis.
Chronic inflammation and immune activation associated with HIV has several systemic effects on the body and the vascular system; in addition, it can target specific cells that are involved in atherosclerosis and other vascular pathology. For example, HIV patients are at increased risk for insulin resistance and diabetes mellitus, with rates of diabetes mellitus reportedly ranging from 2% to 14%. 26 Chronic inflammation and immune dysregulation may play a role in the development of insulin resistance and glucose dysregulation. 27, 28 B. Cell-specific effects of HIV. In addition to causing systemic effects, HIV affects the vascular system through direct targeting of various cells (Table I ; Fig 2) . This leads to cholesterol accumulation, inflammation, and atherosclerosis, which can cause a variety of vascular complications, including coronary artery disease, peripheral artery disease, and kidney disease.
1. Macrophages and HIV. HIV targets macrophages through several mechanisms, resulting in macrophage activation, cholesterol accumulation within macrophages, and impaired egress of macrophages from the subendothelial space. The HIV viral protein gp120 is a glycoprotein that is part of the outer layer of the virus. It presents itself as three molecules of gp120 that is anchored by gp4 protein, through which it can infect host cells (Fig 3) . 41 The virus activates macrophages via the gp120 pathway. 23 Activated monocytes produce inflammatory cytokines and express activation markers such as CD38, CD69, and CD11b. 15 HIV patients exhibit these inflammatory markers, indicating the presence of activated macrophages. Moreover, sICAM-1 and vascular cell adhesion molecule 1 (VCAM-1), markers of activation of the endothelium, are elevated in HAART-naïve, HIV-positive patients. 15 HIV also causes cholesterol accumulation in macrophages by blocking reverse cholesterol transport from macrophages. Testing HIV-infected macrophages in vitro, Mujawar et al 29 identified a mechanism for this cholesterol accumulation in macrophages. Nef, an accessory viral protein that is produced by cells infected with HIV, disrupts adenosine 5 0 -triphosphate-binding cassette transport A1 (ABCA-1), which affects cholesterol transport in macrophages. ABCA-1 is involved in lipidation of lipid-poor apoA-I, and Nef inhibits cholesterol efflux of apoA-I, implying that ABCA-1 is targeted by Nef. Moreover, Mujawar et al 29 found that Nef downregulates ABCA-1 and causes intracellular redistribution of ABCA-1, resulting in the accumulation of cholesterol in macrophages.
HIV can cause plaque development. HIV-infected and Nef-transfected macrophages accumulate lipids and resemble foam cells. 29 These macrophages lead to increased plaque development, contributing to HIV-specific atherosclerosis. There is evidence to suggest, moreover, that atherosclerotic plaques in HIV-positive individuals are structurally different from those in HIV-naïve patients 10 and may consist primarily of inflammatory lesions (ie, macrophages) compared with traditional atherosclerosis.
Finally, HIV leads to impaired egress of HIV-infected macrophages from the subendothelial space. HIV infection induces expression of integrins, such as CD11a/CD18 and CD11b/CD18, which promote monocyte adhesion to the endothelium. 15, 30, 31 In an in vitro study using human umbilical vein EC monolayers, Westhorpe et al 32 demonstrated that HIV impairs transendothelial migration back into the bloodstream.
The above effects of HIV target type I macrophages, or classically activated macrophages (M1). HIV, however, also affects the anti-inflammatory properties of type II macrophages, or alternatively activated macrophages (M2). Herbein and Varin 42 proposed a mechanism by which HIV infection activates macrophages: in the early stage of disease, M1 macrophages are activated, causing inflammation and expression of various inflammatory markers; in the intermediate stage, macrophages are activated mostly via the alternative pathway, which has anti-inflammatory properties; finally, in the late stage of disease progression, macrophages are deactivated. The alternative activation pathway is mediated through IL-4 and IL-13, and these cytokines counteract the proinflammatory actions of IL-1. 42 2. ECs and HIV. HIV is associated with endothelial activation and apoptosis through several proposed mechanisms. HIV tat protein and inflammatory markers can activate ECs. 23 With TNF-a, HIV tat protein activates ECs via nuclear factor-kB, which causes ECs to produce monocyte chemoattractant protein-1, a chemoattractant, ICAM-1, VCAM-1, and e-selectin (leukocyte adhesion molecules). This causes the recruitment and adhesion of atherogenic monocytes (Fig 2) . 23 Moreover, HIV-Nef can cause endothelial dysfunction. HIV T cells from the Jurkat cell line, when in contact with epithelium, have been shown to act with Nef as major EC activators. Nef induces the generation of reactive oxygen species and the release of monocyte chemoattractant protein-1. 33 Similar to macrophage activation, HIV acts through gp120 to cause endothelial dysfunction. 34 In porcine coronary arteries and in human coronary artery ECs, gp120 reduced expression of endothelial nitric oxide synthase (eNOS), which synthesizes nitric oxide (NO), a major mediator of endothelium-dependent vasorelaxation. This mechanism is mediated by ICAM-1, which is produced by HIV-infected ECs. 34 HIV can induce gp120-mediated EC apoptosis in the lungs. 35 The presence of Nef in ECs was sufficient to induce EC apoptosis in vitro. 33 Through disruption of the integrity of the endothelium, gp120-induced apoptosis occurs, which is mediated by the a-chemokine receptor CDCR4. 36 Nef also induces apoptosis of ECs through mechanisms dependent on reactive oxygen species. 33 Wang et al 33 observed that Nef-induced apoptosis of human coronary artery ECs was inhibited completely by Trolox (Sigma-Aldrich, St. Louis, Mo), a vitamin E derivative and reactive oxygen species inhibitor. Thus, reactive oxygen species contribute to apoptosis of ECs.
3. SMCs and HIV. SMCs are also susceptible to HIV in terms of activation, proliferation, and migration. HIV contributes to SMC proliferation via the gp120 mechanism. Unusual smooth muscle proliferation with luminal protrusions has been reported in the coronary artery of ECs, Endothelial cells; SMCs, smooth muscle cells.
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HIV-infected patients. 37 As presented previously, HIV gp120 reduces eNOS expression and thus synthesis of NO. NO regulates vascular homeostasis, including inhibition of SMC proliferation. Thus, with eNOS inhibition, there is a tendency toward SMC proliferation. 34 HIV envelope protein gp120 activates SMCs to express tissue factor. 38 Tissue factor initiates the coagulation cascade. This occurs in conjunction with activation of mitogen-activating protein kinases, activation of protein kinase C, and generation of reactive oxygen species. 38 These mechanisms induce clotting to the vessels where atherogenic plaque has already negatively affected circulation in addition to the risk of coronary disease, stroke, and peripheral vascular pathology.
4. Platelets and HIV. HIV damages platelets, contributing to atherosclerotic plaque development. HIV-infected -1) , and e-selectin to further activate monocytes. HIV membrane protein gp120 activates monocytes that, together with MCP-1, ICAM-1, VCAM-1, and e-selectin increase diapedesis through the endothelium; HIV integrins further impair the macrophages. This leads to increased cholesterol buildup within macrophages and limits the egress of HIV-infected macrophages from the subendothelial space. B, Increased levels of gp120 in the media lead to decreased nitric oxide (NO), furthering the proliferation of SMC and migration into the atherosclerotic plaque.
patients exhibit higher levels of platelet-associated immunoglobulins. Studies have also found elevated levels of circulating immune complexes, which may mediate damage to platelets. 39 Furthermore, HIV gp120-induced inhibition of eNOS activity reduces NO-mediated inhibition of platelet adhesion and aggregation. 34 A study of HIV patients treated with HAART and HAART-naïve HIV patients found that HIV-1 induced platelet activation. 40 Both HIV populations showed increased soluble CD40 ligand, a systemic marker of platelet activation. However, HAART-naïve patients had significantly higher platelet oxidative stress, as measured by platelet NOX2-derived peptide and platelet prostaglandin F 2a . This study concluded that HIV-1 enhances platelet NOX2 activity and, thus, that platelet activation is dependent on platelet oxidative stress. 40 
II. HAART effects on vasculopathy/pathogenesis
A. Metabolic/systemic effects of HAART. Antiretrovirals may be an independent risk factor for cardiovascular disease, as assessed by a comparative ultrasound study of 132 HIV-infected patients with or without exposure to HAART. 43 Research suggests that antiretrovirals, particularly PIs, contribute to dyslipidemia in HIV patients, primarily though interactions with cholesterol metabolism. However, some HAART medications are more harmful than others to the vascular system. For instance, atazanavir is less harmful than indinavir or rionavir. PI-induced dyslipidemia can result in the development of lipodystrophy, hypercholesterolemia, hypertriglyceridemia, hypolipoproteinemia, and insulin resistance. 15 These conditions can have serious effects on the vascular system.
Although the mechanisms of PI-induced dyslipidemia are not well understood, there are several putative mechanisms (Table II) . PIs can cause inhibition of degradation and secretion of apoB, a component of lipoproteins that is a determinant of activated plasma lipid levels. PIs stabilize apoB levels intracellularly; however, they reduce apoB secretion, leading to elevated levels of lipid within the blood stream. This increases LDL and very-LDL (VLDL) secretion.
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PIs may also result in increased VLDL levels. A study comparing various parameters of apoB metabolism in patients treated with PIs vs those treated with dual nucleoside reverse transcriptase inhibitors (NRTIs) found that patients treated PIs had significantly higher levels of VLDL-apoB and intermediate-density lipoprotein-apoB concentrations. 44 Clearance of LDL is affected by the use of some PIs by decreased LDL receptor (LDLR) and LDLR-related protein. 45 Nelfinavir, for instance, significantly decreases LDLR and LDLR-related protein messenger (m)RNA and protein levels, resulting in the reduced functional activity of these two receptors. Nelfinavir exerts its effect by reducing levels of active sterol regulatory elementbinding transcription factor 1 in the nucleus. This may ultimately result in decreased LDL clearance and hypercholesterolemia.
Blocked adipogenesis and increased lipolysis are seen in HIV patients taking saquinavir, another PI. Saquinavir affects not only the metabolic (mitochondrial) activity of adipocytes but also the expression of genes related to differentiation and to a lesser extent to cell apoptosis. 46 In addition, certain PIs stimulate triglyceride synthesis. Some PIs (ABT-378, nelfinavir, ritonavir, and saquinavir) stimulated triglyceride synthesis. Another (ritonavir) increased cholesterol synthesis. 47 Nelfinavir increased mRNA expression of diacylglycerol acyltransferase and fatty acid synthase. Overall, PIs could increase hepatic triglyceride synthesis, resulting in hyperlipidemia. 
Table II. Effects of protease inhibitors (PIs) on lipid metabolism

Effect of PIs on lipid metabolism
Inhibition of degradation and secretion of apoB 11 Impairment of cholesterol processing and triglyceride clearance 44 Decreased clearance of LDL 45 Blockage of adipogenesis and increased lipolysis 46 Stimulation of triglyceride synthesis 47 apo, Apolipoprotein; LDL, low-density lipoprotein.
PIs have been linked to insulin resistance and diabetes mellitus in HIV patients. Rates of insulin resistance among HIV patients treated with HAART range from 35% to 63%; however, this rate has decreased with the development of newer HAART regimens. 26 Antiretroviral drugs that cause less metabolic toxicity potentially are least likely to cause insulin resistance. 26 B. Cell-specific effects of HAART. Like HIV, antiretrovirals can target macrophages, ECs, and SMCs, which can also contribute to atherosclerosis. However, much of the data on these effects come from in vitro or mouse studies; in humans, how much HAART-induced atherosclerosis and dyslipidemia is attributable to cell-specific vs systemic effects is not always clear.
1. Macrophages and HAART. PIs have been shown to promote the formation of atherosclerotic lesions by increasing cholesterol accumulation in macrophages. Incubation of human peripheral blood mononuclear cells and THP-1 cells with PIs significantly increases amounts of cell-associated cholesteryl ester. 48 Mouse studies have revealed that PIs promote the creation of lipid-laden macrophages independent of PI-induced dyslipidemia. 48 PIs upregulate CD36 levels in macrophages, which in turn causes accumulation of cholesterol esters within macrophages in vitro. 48 Moreover, HAART inhibits cholesterol efflux from human macrophage-derived foam cells in vitro by limiting expression of caveolin-1, a key mediator in cholesterol efflux. 49 Yet, Mukhamedova et al, 50 testing concentrations of seven different antiretroviral drugs on mouse macrophages and human-derived macrophages, found that these compounds had no effect on cholesterol. Moreover, El Khoury et al 51 determined that HAART initiation actually helped to facilitate cholesterol efflux compared with the cholesterol accumulation within macrophages caused by the HIV virus itself. Thus, the exact effects of HAART on cholesterol accumulation in macrophages are currently unresolved.
2. ECs and HAART. Patients treated with HAART initially show signs of improvement of endothelial activation and dysfunction. 52 Wolf et al 53 showed that patients newly on HAART therapy (mean duration, 9 months) had decreased sICAM-1 and sVCAM-1 levels. Theoretically, this indicates that HAART helps to counteract the effects of HIV on ECs. However, patients on HAART long-term exhibit signs of endothelial dysfunction.
Antiretrovirals can induce endothelial dysfunction, affecting endothelium-dependent vasorelaxation, the eNOS system, and the reduction/oxidation system. 54 Several studies have shown flow-mediated vasodilation is impaired after exposure to PIs. 55 Mice treated with azidothymidine, an NRTI, experienced impaired endothelium-dependent vessel relaxation. 12 Furthermore, several PIs independently reduced endothelium-dependent vasorelaxation in porcine carotid arteries. 55 A study of endothelium dependent and independent vasodilation of the brachial artery in 27 HIV-positive patients and 16 controls found that HIVpositive patients treated with PIs had significantly lower endothelium-independent vasodilation than the HIVnegative patients and HIV-positive patients not taking PIs. 56 PIs also affect the eNOS/NO system. A study of porcine carotid arteries found that PIs decreased eNOS expression and expression of eNOS mRNA, thus decreasing NO expression. 55 This could contribute to reduced vasorelaxation in human arteries.
PIs contribute to enhanced formation of reactive oxygen species, which can injure the vasculature through several mechanisms, including disturbing organ perfusion, hypertension, inflammation, apoptosis, and initiation of damaging intracellular signaling. 55 Another study of porcine carotid arteries found increased levels of reactive oxygen species after treatment with PIs.
Moreover, Shankar et al 52 found a 60% impairment in endothelium-dependent vasodilation in HIV-negative subjects taking a 4-week course of inadovir, a PI. They further observed a nearly complete abrogation of NO-dependent vasodilator tone. 52 It is also possible that the endothelial dysfunction seen in HAART treated patients is a result of HAART-induced insulin resistance or dyslipidemia in addition to the effects of HAART directly on ECs. More research is needed to examine the differing results of these effects of HAART.
3. SMCs and HAART. PI-induced injury to the endothelium can result in SMC proliferation, along with other effects such as lipid accumulation and monocyte infiltration. HAART exacerbates injury-induced vascular SMC proliferation and neointimal hyperplasia in coculture with ECs and in mice. 12, 57 In a mouse model, Jiang et al 58 found that the PI idinavir and the NRTI azidothymidine (together or separately) significantly increased aortic intima media thickness and cross-sectional area. These findings may help explain the atherosclerosis observed in HIV patients treated with HAART.
III. Translational clinical applications
A. Rates of vasculopathy in HIV/AIDS patients. Rates of cardiovascular pathologies in HIV patients are increasing because patients are living longer due to early detection and the effectiveness of HAART. The prevalence of cardiovascular disease, coronary heart disease, myocardial infarction, atherosclerosis, and peripheral artery disease is elevated in the HIV-infected population. 4, [59] [60] [61] In 2010, cardiovascular diseases accounted for 10% of deaths among HIV-infected patients in France. 62 Because the etiology of vascular disease is often different in HIV-infected individuals, traditional risk calculators for cardiovascular disease may be insufficient, and it is important to keep in mind that HIV patients may not be accurately stratified using traditional measurements. 63 B. Clinical presentation. HIV patients may present with a variety of symptoms or conditions that increase their cardiovascular risk profile. HIV-infected patients treated with HAART may demonstrate venous thrombosis, peripheral artery disease, stroke, and myocardial infarction. [64] [65] [66] These patients may also present with occlusive disease, aneurysms, or spontaneous atriovenous fistula. One study of 109 HAART-naïve, HIV-infected patients who received a vascular surgery intervention found that 22% had aneurysmal disease and 61% had occlusive disease. 67 Patients with aneurysms often had multiple aneurysms and aneurysms in unusual locations.
Notably, HIV-infected individuals do not appear to be at increased risk for valvular diseases compared with the general population. 68 Moreover, in countries with widespread use of HAART, the incidences of other cardiovascular pathologies that are associated with AIDS have decreased. For instance, rates of pericardial disease, myocarditis, and cardiomyopathy have decreased significantly in resource-rich countries but are still common in research-limited settings. 69 Lipodystrophy is observed in HAART-naïve patients and in patients receiving HAART. Before the advent of HAART, advanced AIDS-associated lipodystrophy was characterized by severe wasting and low cholesterol levels. 70 However, HAART has also been associated with lipodystrophy, with rates ranging from 10% to 80%. [71] [72] [73] [74] HAART-associated lipodystrophy may be a result of exposure to NRTIs or other HAART agents. This includes lipoatrophy or abnormal fat accumulation. 75 HIV-infected patients treated with HAART may also present with metabolic disorders associated with lipodystrophy, such as insulin resistance, diabetes mellitus, high triglyceride levels, and low HDL levels. [76] [77] [78] HIV patients may have higher rates of hypertension than the general population. One study of billing codes identified hypertension in 21% of HIV-infected patients compared with 16% of uninfected patients. 5 C. Treatment. Although more research is needed into treatments for HIV-induced vasculopathy, several strategies have been shown to be somewhat effective for this population. HIV patients should be counseled on lifestyle changes to reduce the effects of traditional risk factors for vascular disease. Among certain populations, HIV patients have higher rates of smoking compared with the general population. 79 When applicable, HIV patients should be encouraged to stop smoking, exercise, and maintain a healthy diet to reduce their cardiovascular risk profile. Aspirin, statin use, and blood pressure control may also be useful preventative measures.
HIV-patients should be treated with HAART, not only to slow the progression of the virus but also to lower the effect of HIV-specific vasculopathy. Despite the effects of HAART on the vascular system, multiple studies have shown that initiation of HAART lowers cardiovascular risk overall. 80 However, selecting appropriate HAART regimens for high-risk patients is important. Patients treated with PIs overall have a higher risk of cardiovascular disease than those treated with non-NRTIs. 81 There is some evidence to suggest that statin therapy may be useful to lower cardiovascular risk in HIV patients. 81 Two small, randomized controlled trials have suggested that statins may lower the risk of cardiovascular disease in HIV patients. 82, 83 A larger trial, Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), plans to enroll 6500 participants to evaluate these findings in a larger population. 84 However, some statins may increase the risk of insulin resistance and diabetes, another area for future study. 81 Patients with subclinical vasculopathy or risk for vasculopathy should be managed and monitored for the development of clinically significant pathology.
Surgical intervention may be riskier for HIV-infected patients. Botes and Van Marle 67 had poor surgical success with HIV-positive patients with aneurysms, occlusive disease, and atrial-venous fistula, reporting a >75% failure rate for bypass surgery in these patients. However, this high failure rate may be due to the immunocompromised state of HIV-infected patients: outcomes were similar compared with other immunocompromised patients undergoing vascular surgery, and other authors have reported similar outcomes among patients positive and negative for HIV. 63, 85 CONCLUSIONS HIV patients have increased risk of developing potentially life-threatening cardiovascular pathology, which cannot be explained by traditional cardiovascular risk factors alone. HIV itself has both direct and indirect effects on the vascular system. Chronic inflammation associated with HIV can lead to macrophage activation and plaque development. HIV can induce dyslipidemia. In addition, HIV affects cells associated with atherosclerosis, such as platelets, macrophages, SMCs, and ECs. Through activation and apoptosis of certain cells, HIV can induce plaque development. Unfortunately, PIs and other forms of HAART used to help the HIV-infected patient can cause dyslipidemia by affecting cholesterol metabolism and clearance, lipolysis, and triglyceride synthesis, in addition to targeting the same cells affected by the virus.
Management of these vascular complications is difficult because causes are so multifactorial. Use of HAART to combat the HIV virus and lower viral loads can help reduce chronic inflammation and prevent HIV-specific contributions to vasculopathies. The use of certain HAART regimens, such as atazanavir, may be considered, because they are less likely to cause adverse vascular effects. Adding medications to combat dyslipidemia, such as statins, may be useful.
There is still much research to be done on the effects of HIV and HIV treatment medications that leads to the development of cardiovascular dysfunction in HIVinfected individuals. Future directions of research include a thorough analysis of the mechanisms by which PIs affect cholesterol metabolism and investigations into new treatment modalities for HIV-infected individuals experiencing vascular complications.
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